Open an account

Natera

NTRA · NASDAQ

$405.92+$6.50 (+1.63%)TodayMarket closed ·
Prev close $399.42

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. The company is headquartered in Austin, Texas and currently employs 6,135 full-time employees. The company went IPO on 2015-07-02. The firm's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. The company has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.

Employees
6,135
Headquarters
Austin, Texas
Listed
Jul 2, 2015
Sector
Health Care
Industry
Biotechnology
Website
natera.com

NTRA key statistics

Market cap
57.57B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.74M
Volume
573.39K
Open price
$400.01
High today
$410.28
Low today
$396.09
52 Week high
$437.41
52 Week low
$178.01

Natera (NTRA) at a glance

Natera (NTRA) last traded at $405.92, with a market cap of 57.57B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $396.09 and $410.28. The current price is 2.5% above the day's low and 1.1% below its high.

Volume so far is 573.39K shares, below the average of 1.74M shares a day.

Over the past year Natera has ranged from $178.01 to $437.41, and now sits 88% of the way up that range.

Natera met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.47 per share against an estimate of -$0.5036.

The average analyst price target is $360.94, 11.1% below the current price, from 24 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

88%of 24 analyst ratings say Buy
  • Buy87.5%
  • Hold12.5%
  • Sell0.0%
Price target · 25 analystsAvg $360.94
Low
$282.80
Now
$405.92
High
$483.00

NTRA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 63.6% on average.

  1. Q3 FY24: reported -$0.26 per share against an estimate of -$0.5863
  2. Q4 FY24: reported -$0.41 per share against an estimate of -$0.3989
  3. Q1 FY25: reported -$0.50 per share against an estimate of -$0.6499
  4. Q2 FY25: reported -$0.74 per share against an estimate of -$0.6283
  5. Q3 FY25: reported -$0.64 per share against an estimate of -$0.3805
  6. Q4 FY25: reported $0.36 per share against an estimate of -$0.5208
  7. Q1 FY26: reported -$0.60 per share against an estimate of -$0.5471
  8. Q2 FY26: reported -$0.47 per share against an estimate of -$0.5036

NTRA news

  • Press releaseBusiness Wire

    ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

  • Press releaseBusiness Wire

    Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026

  • Press releaseBusiness Wire

    Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

  • Press releaseBusiness Wire

    FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay

  • Press releaseBusiness Wire

    Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma

  • Press releaseBusiness Wire

    New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists

  • Press releaseBusiness Wire

    Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

  • Chris Katje

    Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You

Similar companies

Companies in the same industry as Natera

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.